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Effects of elamipretide on skeletal muscle in dogs with
experimentally induced heart failure
Hani N. Sabbah*, Ramesh C. Gupta, Vinita Singh-Gupta and Kefei Zhang
Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
Abstract
Aims Elamipretide (ELAM), an aromatic–cationic tetrapeptide, interacts with cardiolipin and normalizes dysfunctional
mitochondria of cardiomyocytes. This study examined the effects of ELAM on skeletal muscle mitochondria function in dogs
with chronic heart failure (HF).
Methods and results Studies were performed in skeletal muscle biopsy specimens obtained from normal dogs (n = 7) and
dogs with chronic intracoronary microembolization-induced HF (n = 14) treated with subcutaneous ELAM 0.5 mg/kg
(HF + ELAM, n = 7) or vehicle (normal saline control, HF-CON, n = 7). After 3months of therapy, triceps skeletal muscle samples
were obtained from all dogs, and the proportion of type 1 and type 2 fibres was assessed. Mitochondria isolated from myo-
fibrils of the vastus lateralis skeletal muscle exposed in vitro to ELAM for 1 h were used to assess mitochondrial function. The
proportion of skeletal muscle type 1 fibres was lower in HF-CON dogs compared with normal dogs (23 ± 4 vs. 32 ± 5%,
P < 0.05). Treatment with ELAM restored a near-normal fibre-type composition (31 ± 7%, P < 0.05 vs. HF-CON). Skeletal mus-
cle mitochondria showed significantly lower levels of adenosine diphosphate-dependent mitochondrial respiration (100 ± 9 vs.
164 ± 15 natom O/min/mg protein, P < 0.05), mitochondrial membrane potential (0.17 ± 0.03 vs. 0.53 ± 0.03 red/green fluo-
rescence ratio, P < 0.05), mitochondrial permeability transition pore (38 ± 3 vs. 62 ± 2 relative light units, P < 0.05), maximum
rate of adenosine triphosphate synthesis (3284 ± 418 vs. 8835 ± 423 RLU/μg protein, P < 0.05), and cytochrome c oxidase
activity (1390 ± 108 vs. 2459 ± 210 natom O/min/mg protein, P< 0.05) compared with normal dogs. Exposure of skeletal mus-
cle myofibrillar mitochondria from HF dogs to ELAM showed a dose-dependent improvement/normalization of all measures of
mitochondrial function. In mitochondria from skeletal muscle of HF dogs exposed to 0.10 μM ELAM, adenosine diphosphate-
dependent mitochondrial respiration increased to 183 ± 18 natom O/min/mg protein, membrane potential increased to
0.30 ± 0.03 red/green fluorescence ratio, mitochondrial permeability transition pore increased to 54 ± 4 RLU, maximum rate
of adenosine triphosphate synthesis increased to 4423 ± 414, and cytochrome c oxidase activity increased to 2033 ± 191 natom
O/min/mg protein. Exposure of skeletal muscle myofibrillar mitochondria from normal dogs to ELAM had no effect on
mitochondrial function parameters.
Conclusions The results indicate that ELAM, previously shown to positively influence mitochondrial function of the failing
heart, can also positively impact mitochondrial function of skeletal muscle and potentially help restore skeletal muscle function
and improve exercise tolerance.
Keywords Heart failure; Mitochondria; Skeletal muscle; Energy metabolism; Animal models; Exercise tolerance
Received: 15 June 2018; Accepted: 12 December 2018
*Correspondence to: Hani N. Sabbah, Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202,
USA. Tel: (313) 916 7360; Fax: (313) 916 3001. Email: hsabbah1@hfhs.org
ORIG INAL RESEARCH ART ICLE
© 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
ESC HEART FAILURE
ESC Heart Failure 2019; 6: 328–335
Published online 28 January 2019 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.12408
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any me-
dium, provided the original work is properly cited and is not used for commercial purposes.
Introduction
Functional mitochondria are necessary for optimal energy
production and organ function, and their dysfunction can
have a profound effect on many serious disease states that
include chronic heart failure (HF) and skeletal muscle myopa-
thies with associated fatigue and exercise intolerance.1,2 In
the healthy heart, optimal generation of adenosine triphos-
phate (ATP) by mitochondria sustains excitation–contraction
coupling and supports normal cardiac function.3 Dysfunc-
tional mitochondria in HF reduce the capacity for on-demand
cardiac ATP generation, leading to an energy-deficit state and
dysfunction of both cardiac and skeletal muscle.3 Dysfunc-
tional mitochondria also lead to increased formation of reac-
tive oxygen species (ROS)4,5 that can potentially cause further
injury to mitochondrial membrane structures and lead to fur-
ther worsening of the bioenergetic state believed to be a pri-
mary factor in HF progression.
Exercise intolerance is a hallmark of chronic HF. A com-
plete understanding of the possible haemodynamic, struc-
tural, and molecular abnormalities that lead to exercise
intolerance in HF is lacking. The observation of a poor corre-
lation between central haemodynamics and exercise intoler-
ance in patients with HF shifted interest to peripheral
factors that include skeletal muscle structure and metabolism
and to other factors that include iron deficiency, muscle atro-
phy and loss, abnormal muscle function, decreased capillary
density, and endothelial dysfunction.6–11 Along these lines,
exercise intolerance in HF has been attributed to skeletal
muscle atrophy, a shift from slow-twitch type 1 (oxidative)
to fast-twitch type 2 (glycolytic) muscle fibres, mitochondrial
abnormalities, and increased expression of inducible nitric ox-
ide synthase (iNOS) with the resulting increase in nitric oxide,
causing a decrease in mitochondrial creatine kinase, a key en-
zyme necessary for the transfer of high-energy phosphates
from mitochondria to cytosol.12–16
Elamipretide (ELAM, also known as MTP-131, SS-31) is an
aromatic–cationic tetrapeptide that readily crosses the plasma
membrane and localizes to the inner membrane of mitochon-
dria via its selective, transient binding to cardiolipin.17
Through interaction with cardiolipin, ELAM increases the elec-
tron flux through cytochrome c and reduces electron leak.18
Elamipretide has also been shown to improve mitochondrial
respiration, reduces the production of reactive oxygen species,
and increases the maximum rate of ATP synthesis in dysfunc-
tional mitochondria while having no effect on normal healthy
mitochondria.17,19–22 The present study was designed to eval-
uate the effects of ELAM on skeletal muscle fibre-type compo-
sition and mitochondrial function in dogs with chronic HF.
Methods
All studies were performed in skeletal muscle biopsy specimens
obtained from normal dogs (n = 7) and dogs with chronic
intracoronary microembolization-induced HF (n = 14). All dogs
were fed the same diet throughout the study (Purina Pro Plan
Sport, Nestle Purina PetCare Company, St. Louis, MO). The ca-
nine model of chronic HF used in this study was previously de-
scribed in detail.23 In this study, 14 healthy purpose-bred class
A dealer mongrel male dogs, weighing between 20.8 and
25.7 kg, underwent serial intracoronary microembolizations,
performed 1 to 2 weeks apart, to produce chronic HF. Emboli-
zations were discontinued when left ventricular ejection frac-
tion, determined angiographically, was ~30%. The study was
approved by the Henry Ford Health System Institutional Animal
Care and Use Committee and conformed to the National Insti-
tute of Health ‘Guide and Care for Use of Laboratory Animals’
(NIH Publication No. 85-23). Six weeks after the last
microembolizations, HF dogs were randomized to 3 months
of therapy with subcutaneous injections of ELAM (0.5 mg/kg
once daily, n = 7, HF + ELAM) or subcutaneous injections of sa-
line as vehicle (once daily, n = 7). Vehicle-treated HF dogs
served as controls (HF-CON). The haemodynamic, ventriculo-
graphic, and echocardiographic findings in these dogs, as well
as the cardiac mitochondrial function measures, were previ-
ously reported.24
Measurements of skeletal muscle fibre-type
composition
At the end of 3 months of therapy, and after completing the
final haemodynamic study (while the dog was under general
anaesthesia), triceps skeletal muscle samples were obtained
from all 14 HF dogs using an open biopsy procedure, as pre-
viously described.13 Triceps skeletal muscle samples from
seven normal dogs were also obtained and used for compar-
isons. Skeletal muscle type 1 and type 2 fibres were differen-
tiated histologically by myofibrillar adenosine triphosphatase
staining.13 The proportion of type 1 and type 2 fibres and
the average cross-sectional area of each fibre type was
assessed in five randomly selected skeletal muscle
fields/dogs each containing ~100 fibres.
Measurements of skeletal muscle mitochondrial
function
Skeletal muscle biopsies
Fresh skeletal muscle open biopsies (~6 g each) were ob-
tained from the hind leg vastus lateralis muscle of six normal
(NL) and six untreated HF anaesthetized dogs. Specimens
were immersed in Solution A (consisting of 20 mM
imidazole–HCl, 0.16 mM MES, 5 mM ATP, 7.5 mM phospho-
creatine, 0.5 mM DTT, 20 mM taurine, 3 mM MgCl2, and
10 mM EGTA at pH = 7.4). Myofibre bundles were subse-
quently isolated as previously described.25 Briefly, tissue
was cut into 100- to 200-μm-thin longitudinal sections and
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washed two times with Buffer A and subsequently washed
once with Buffer B consisting of 10 mM EGTA, 3 mM MgCl2,
20 mM taurine, 0.5 mM DTT, 20 mM imidazole, 0.16 mM
MES, and 10 mg/mL bovine serum albumin at pH = 7.4.
Myofibre bundles were then divided into four equal portions
and each resuspended in 20 mL of Solution B. One portion of
each was incubated in 0 (vehicle–saline), 0.01, 0.10, and
1.0 μM concentration of ELAM, respectively, for 1 h at 37°C.
Isolation of mitochondria
After treatment, skeletal muscle fibres were washed and re-
suspended in 10 mL CP2 medium (100 mM KCl, 50 mM
MOPS, 5 mM MgSO4·7H2O, 5 mM potassium phosphate,
5 mM ATP, and +200 mg bovine serum albumin, pH = 7.4)
followed by homogenization by polytron at Setting 4 for
10 min and three strokes using a Potter Elvejhem homoge-
nizer (Setting 60). The homogenate was then centrifuged at
584 g for 10 min. The pellet was discarded, and the superna-
tant was centrifuged at 3000 g for 10min. The resulting pellet
was washed once with 10 mL consisting of buffer 100 mM
KCl, 5 mM MOPS, and 0.5 mM EGTA, pH = 7.4 and finally
resuspended in a small volume (200 μL) of the same buffer.
Mitochondrial function
Isolated mitochondria were used to determine several mea-
sures of mitochondrial function as previously described.16
The measures included (i) ADP-dependent mitochondrial res-
piration as previously described using a Strathklein respirom-
eter; (ii) maximum rate of ATP synthesis (ATPsyn) using the
bioluminescent ApoSENSOR assay kit (BioVision, Milpitas,
CA)26; (iii) cytochrome c oxidase (COX-IV) activity measured
polarographically; (iv) mitochondrial membrane potential
(Δψm) measured using the commercially available JC-1 cat-
ionic fluorescent dye kit (Sigma, St. Louis, MO)26; and (v) mi-
tochondrial permeability transition pore (mPTP) opening
assessed using a MitoProbe Transition Pore assay kit (Molec-
ular Probes, Eugene, OR, USA Cat# M34153).26
Western blotting
Skeletal muscle specimens were used to assess protein levels
of iNOS and β-actin (an internal control). Protein measure-
ments of iNOS were normalized to β-actin to adjust for load-
ing conditions. Isolated mitochondria from skeletal muscle
were also used to examine protein levels of indicators of cel-
lular apoptosis, specifically protein levels of cytochrome c and
levels of HtrA2, a proapoptotic mitochondrial serine protease
involved in caspase-dependent and caspase-independent cell
death. Levels of cytochrome c and HtrA2 were normalized to
porin, a mitochondrial outer membrane protein that is un-
changed in HF. Levels of all proteins were determined by
western blotting and bands quantified in densitometric
units.24 Primary antibodies for HtrA2 and cytochrome c were
obtained from Santa Cruz, CA, antibody for porin from
Abcam, Cambridge, MA, and antibodies for iNOS from
LifeSpan Biosciences, Inc., Seattle, WA.
Statistical analysis
Within each group, comparisons of mitochondrial functional
measures were made using repeated measures analysis of var-
iance (ANOVA) with α set at 0.05. If significance was attained,
pairwise comparisons between no treatment and each escalat-
ing ELAM treatment concentration were made using the
Student–Newman–Keuls test with P < 0.05 considered signifi-
cant. Comparisons of biochemical and histomorphometric
measures between normal, HF-CON, and HF + ELAM dogs were
made using one-way ANOVA with α set at 0.05. If significance
was attained by ANOVA, pairwise comparisons were performed
using the Student–Newman-Keuls test with P < 0.05 consid-
ered significant. Comparisons of baseline levels (no ELAM expo-
sure) between normal and HF dogs for all mitochondrial
functional measures were made using a t-statistic test for two
means with P < 0.05 considered significant. The study was
not blinded, and all data are reported as mean ± standard error
of the mean.
Results
Histomorphometric findings
The proportion of skeletal muscle type 1 fibres was lower and
type 2 fibres higher in HF-CON dogs compared with normal
dogs (Table 1 and Figure 1), leading to a significantly lower
fibre-type ratio. Treatment with ELAM restored a near-
normal fibre-type composition. There were no differences in
fibre cross-sectional area among study groups (Table 1).
Mitochondrial function measures and complex IV
activity
At baseline (no exposure to ELAM), skeletal muscle mitochon-
dria from dogs with HF showed significantly lower levels of
ADP-dependent mitochondrial respiration, Δψm, mPTP,
maximum rate of ATPsyn, ATP/ADP ratio, and COX-IV activity
(Figures 2 and 3). Exposure of skeletal muscle myofibrillar mi-
tochondria from normal dogs to ELAM for 1 h at concentra-
tion of 0.01 to 1.0 μM had no effect on any of the
mitochondrial function parameters measured in this study
(Figures 2 and 3). In contrast, exposure of skeletal muscle
myofibrillar mitochondria from HF dogs to ELAM showed a
dose-dependent improvement/normalization of all measures
of mitochondrial function. For all measures, statistical signifi-
cance was attained at ELAM concentration of 0.1 and 1.0 μM.
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Table 1 Skeletal muscle fibre-type distribution and inducible nitric oxide synthase isoform level in normal, HF-CON (n=7), and HF+ ELAM
(n = 7) dogs
Normal HF-CON HF + ELAM
Type 1 skeletal muscle fibres (%) 32 ± 5 23 ± 4* 31 ± 7**
Type 2 skeletal muscle fibres (%) 68 ± 5 77 ± 4* 69 ± 7**
Skeletal muscle type 1/type 2 ratio 0.47 ± 0.04 0.30 ± 0.07* 0.45 ± 0.13**
Average CSA type 1 fibres (μm2) 2996 ± 176 2057 ± 415 3058 ± 354
Average CSA type 2 fibres (μm2) 3445 ± 240 3560 ± 378 3495 ± 258
CSA type 1/CSA type 2 ratio 0.88 ± 0.03 0.86 ± 0.05 0.87 ± 0.04
β-Actin (du) 2.22 ± 0.11 2.36 ± 0.20 2.37 ± 0.10
iNOS/β-actin 0.71 ± 0.08 2.01 ± 0.21* 1.16 ± 0.08*,**
Porin (du) 0.62 ± 0.13 0.66 ± 0.05 0.64 ± 0.07
Cytochrome c/porin 2.17 ± 0.86 0.49 ± 0.06* 1.20 ± 0.22*,**
HtrA2/porin 2.14 ± 0.49 0.34 ± 0.06* 1.28 ± 0.15*,**
CSA, cross-sectional area; HF-CON, untreated heart failure control; HF + ELAM, elamipretide-treated heart failure; iNOS, inducible nitric
oxide synthase.
*P < 0.05 vs. normal.
**P < 0.05 vs. HF-CON.
Figure 1 Top: ATPase-stained histological panels (same magnification) depict skeletal muscle fibre-type composition in triceps muscle. Type 1 fibres
appear as lightly stained fibres (light brown) and type 2 fibres as dark-stained fibres (dark brown). Left top panel: fibre-type composition in a normal
dog. Top middle panel: fibre-type composition in an untreated heart failure control (HF-CON) dog. Note that the number of type 1 fibres is reduced
relative to normal dogs in the left panel. Top right panel: fibre-type composition in an elamipretide-treated heart failure (HF + ELAM) dog. Note that
the number of type 1 fibres is increased relative to HF-CON in middle panel. The bottom 2 graphs show the numerical distribution (mean ± standard
error of the mean) of skeletal muscle type 1 and type 2 fibres in normal dogs and in both study groups.
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Protein levels of inducible nitric oxide synthase
and indicators of apoptosis
There were no differences in protein levels of the internal
control β-actin between normal, HF-CON, and HF + ELAM
dogs (Table 1). Compared with the skeletal muscle of normal
dogs, levels of iNOS were significantly increased in HF-CON
dogs. Treatment with ELAM reduced protein levels of iNOS
(Table 1).
There were no differences in protein levels of the mito-
chondrial porin between normal, HF-CON, and HF + ELAM
dogs (Table 1). Compared with the skeletal muscle of normal
dogs, levels of cytochrome c and HtrA2 normalized to porin
were significantly reduced in HF-CON dogs. Treatment with
ELAM increased protein levels of both cytochrome c and
HtrA2 normalized to porin (Table 1).
Discussion
In a previous study conducted in our laboratory on dogs with
advanced HF, we showed that long-term therapy with ELAM
improved left ventricular systolic function, normalized plasma
biomarkers, and reversed mitochondrial abnormalities in
cardiomyocytes.24 Based on these results, we designed the
current study to evaluate the effects of ELAM on the skeletal
muscle of dogs with HF. Results of the present study showed
that dogs with HF had a lower proportion of skeletal muscle
type 1 fibres and a higher proportion of skeletal muscle type
2 fibres compared with normal dogs. This type of alteration of
skeletal muscle fibre-type composition is associated with ex-
ercise intolerance in patients with chronic HF.8,16,27 Patients
with chronic HF had a reduced percentage of slow-twitch
type 1 fibres and a higher percentage of fast-twitch type 2 fi-
bres in vastus lateralis skeletal muscle biopsies.16 However,
patients with HF who engaged in regular physical exercise
had enhanced oxidative enzyme activity in skeletal muscle
and a concomitant return to type 1 fibres.16 In addition, pa-
tients with HF also had a reduction in myosin heavy chain
type 1,27 an isoform that is more abundant in skeletal muscle
type 1 aerobic fibres. We previously showed a decrease in the
relative composition of oxidative, slow-twitch, fatigue-
resistant type 1 fibres and an increase in fast-twitch, anaero-
bic, glycogen-dependent type 2 fibres in dogs with coronary
microembolization-induced HF.13 This shift was associated
with reduced exercise tolerance but not with atrophy of
either fibre type.13 The shift in skeletal muscle fibre-type
composition in HF may be partly due to skeletal muscle mito-
chondrial abnormalities with associated reduction of ATP syn-
thesis needed by aerobic type 1 fibres.28 Lack of ATP can lead
to an adaptation of type 1 fibres to utilize glycogen as an en-
ergy source and thus shift towards a fast-twitch phenotype.
Direct support for this, however, remains to be elucidated.
Figure 2 Bar graphs (mean ± standard error of the mean) depicting changes in mitochondrial functional measures of skeletal muscle (SM) myofibrillar
mitochondria of normal and heart failure dogs. Depicted measures are ADP-stimulated respiration (top left), membrane potential (top right), perme-
ability transition pore (mPTP) opening (bottom left), and cytochrome c oxidase (complex IV) activity (bottom right) after exposure to 0.01, 0.10, and
1.0 μM elamipretide. RLU = relative light units.
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In the present study, long-term treatment with ELAM re-
stored skeletal muscle fibre-type composition to a more nor-
mal distribution. Although not confirmed in the present
study, one would speculate this correction or return to nor-
mal skeletal muscle fibre-type distribution would lead to im-
proved exercise tolerance.
The excess formation of ROS by dysfunctional mitochon-
dria contributes to an increase of inner mitochondrial mem-
brane permeability, which leads to a loss of transmembrane
potential and ultimately tissue injury and cell death.29
Heart failure is associated with an opening of the mPTP,
increased levels of cytosolic cytochrome c, and increased
cardiomyocyte apoptosis.8,30,31 In the present study, mea-
surements of cytochrome c and HtrA2 in isolated mitochon-
dria showed a decrease of cytochrome c and HtrA2 in
HF-CON dogs compared with normal dogs, indicating translo-
cation of cytochrome c and HtrA2 from the mitochondria to
the cytosol, the latter a known trigger for activation of
caspase-3-dependent and caspase-3-independent apoptotic
pathways.24,32 Treatment with ELAM increased mitochondrial
levels of cytochrome c and HtrA2, signalling a potential reduc-
tion in the burden of programmed cell death. In this study,
we also showed that exposure of skeletal muscle myofibrillar
mitochondria from dogs with HF to ELAM resulted in a dose-
Figure 3 Bar graphs (mean ± standard error of the mean) depicting changes in mitochondrial functional measures of skeletal muscle (SM) myofibrillar
mitochondria of normal and heart failure dogs. Depicted measures are maximum rate of ATP synthesis (top) and ATP/ADP ratio (bottom) after expo-
sure to 0.01, 0.10, and 1.0 μM elamipretide. RLU = relative light units.
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dependent improvement/normalization of all measures of
mitochondrial function (ADP-dependent mitochondrial respi-
ration, Δψm, mPTP, maximum rate of ATPsyn, ATP/ADP ratio,
and COX-IV activity). These results support those from a pre-
vious study where we showed that chronic ELAM therapy im-
proved the maximum rate of ATP synthesis and increased the
ATP/ADP ratio in the failing myocardium of dogs.24 We also
previously showed that in this same model of HF, chronic
treatment with ELAM improved mitochondria state 3 respira-
tion, Δψm, and mPTP and normalized the activity of complex
I and complex IV in cardiomyocytes, thus limiting the forma-
tion of ROS. The skeletal muscle findings of the present study
suggest that drugs that influence mitochondrial function of
the failing heart can also positively impact mitochondrial
function in peripheral skeletal muscle and potentially restore
function of this muscle group with the potential for improved
exercise tolerance.
Heart failure, regardless of aetiology, is associated with an
enhanced inflammatory state evidenced by an increase in
many proinflammatory cytokines. This proinflammatory state
can lead to increased expression of iNOS, which, in turn, can
result in suppression of mitochondrial respiration.33–35 Previ-
ous studies showed that increased expression of iNOS in skel-
etal muscle of patients with HF was inversely correlated with
mitochondrial creatine kinase expression and exercise capac-
ity.14 In the same study, cell experiments confirmed a causal
relationship via nitric oxide.14 Results from the present study
showed that long-term therapy with ELAM in dogs with HF
was also associated with normalization of iNOS along with
normalization of mitochondrial state 3 respiration and overall
mitochondrial function in skeletal muscle myofibres com-
pared with untreated control dogs.
There are limitations to the study that merit consider-
ations. No measures of overall muscle mass in the dogs were
obtained as part of this study. Also, there were no measures
obtained for the proportion of fat to lean tissue. These mea-
sures would have been helpful for future studies and for
assessing the overall merits of restoration of skeletal muscle
mitochondrial function. The present study also did not
include studies with isolated mitochondria from HF dogs
treated with ELAM. This would have been useful in determin-
ing whether changes in mitochondrial function are sustained
over time. Finally, ultrastructural examination of muscle
fibres and mitochondria in normal, HF, and HF dogs treated
with ELAM would have been useful in supporting the under-
lying hypothesis of the role of mitochondria in skeletal muscle
abnormalities in HF.
In conclusion, the results of this study indicate that long-
term therapy with ELAM, a mitochondria-targeting peptide,
normalized skeletal muscle fibre-type composition and
reversed the increased expression of iNOS in dogs with
chronic HF. Furthermore, the study shows that treatment of
skeletal muscle myofibres with ELAM normalizes mitochon-
drial function. These results, when viewed in concert, suggest
that therapy with ELAM can improve skeletal muscle
morphology and metabolism and, in doing so, potentially
set the stage for an improvement of exercise tolerance, a
key abnormality in HF.
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